Combined Treatment of Bladder Cancer Cell Lines with Lapatinib and Varying Chemotherapy Regimens-Evidence of Schedule-Dependent Synergy

Urology

Volumn 69, Issue 2, 2007, Pages 390-394

  McHugh, Lynsey A ^a   Kriajevska, Marina ^a   Mellon, John K ^a   Griffiths, Thomas R ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; LAPATINIB;

ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; METASTASIS; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYMPTOMATOLOGY;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; QUINAZOLINES; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 33847022350     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.12.003     Document Type: Article

References (27)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics 2002. CA Cancer J Clin 55 (2005) 74-108
2. Loehrer Sr. P.J., Einhorn L.H., Elson P.J., et al. A randomised comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10 (1992) 1066-1073
3. Sternberg C.N., Yagoda A., Scher H.I., et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133 (1985) 403-407
4. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomised trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumours. J Clin Oncol 8 (1990) 1050-1055
5. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomised, multinational, multicentre, phase III study. J Clin Oncol 18 (2000) 3068-3077
6. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001) 127-137
7. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110 (2002) 669-672
8. Junttila T.T., Laato M., Vahlberg T., et al. Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real time reverse transcription PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res 9 (2003) 5346-5357
9. Chow N.H., Chan S.H., Tzai T.S., et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7 (2001) 1957-1962
10. Nguyen P., Swanson P., and Jaszez W. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. Am J Clin Pathol 101 (1994) 166-176
11. Lipponen P., and Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein, (c-erbB-2, p53) expression and longterm prognosis. Br J Cancer 69 (1994) 1120-1125
12. Mellon K., Wright C., Kelly P., et al. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 153 (1995) 919-925
13. Kruger S., Weitsch G., Buttner H., et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 102 (2002) 514-518
14. Memon A.A., Sorensen B.S., Melgard P., et al. Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br J Cancer 91 (2004) 2034-2041
15. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
16. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
17. Wood E.R., Truesdale A.T., Octerloney B., et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64 (2004) 6652-6659
18. Zhou H., Kim Y.-S., Peletier A., et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 58 (2004) 344-352
19. Chu I., Blackwell K., Chen S., et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and oestrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 65 (2005) 18-25
20. Bence A.K., Anderson E.B., Halepota M.A., et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Investig New Drugs 23 (2005) 39-49
21. Spector N.L., Xia W., Burris III H., et al. Study of the biological effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumour growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23 (2005) 1-11
22. Xia W., Mullin R.J., Keith B.R., et al. Anti-tumour activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21 (2002) 6255-6263
23. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations on the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
24. Xu J.-M., Azzariti A., Severino M., et al. Characterization of sequence-dependent synergy between ZD1839 (Iressa) and oxaliplatin. Biochem Pharmacol 66 (2003) 551-563
25. Azzariti A., Xu J.-M., Porcelli L., et al. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with gefitinib (Iressa, ZD1839). Biochem Pharmacol 68 (2004) 135-144
26. Magne N., Fischel J.-L., Tiffon C., et al. Molecular mechanisms underlying the interaction between ZD1839 (Iressa) and cisplatin/5-fluorouracil. Br J Cancer 89 (2003) 585-592
27. Tari A.M., and Lopez-Berestein G. Serum predominantly activates MAPK and Akt kinases in EGFR- and ErbB2-over-expressing cells, respectively. Int J Cancer 86 (2000) 295-297